Physician profile
John Kiraly
NPI 1649238163
$2,697.12
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $89.20 · 2021: $243 · 2022: $427 · 2023: $738 · 2024: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,125 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.16 |
| Education | $154.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $260.31 | 2019-2024 | Imbruvica, Rybrevant, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $211.88 | 2020-2024 | Opdivo, Opdualag |
| Amgen INC. | $195.44 | 2021-2023 | Lumakras |
| Novartis Pharmaceuticals Corporation | $166.45 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $140.10 | 2019-2024 | Keytruda, Lynparza |
| Pfizer INC. | $137.85 | 2019-2023 | |
| Gilead Sciences, INC. | $134.52 | 2022 | |
| Celgene Corporation | $121.82 | 2019-2023 | Reblozyl |
| Intuitive Surgical, INC. | $120.34 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $106.01 | 2022-2024 | |
| Astellas Pharma US INC | $88.71 | 2019-2024 | Xtandi, Padcev, Xospata |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.17 | 2023-2024 | Gilotrif |
| Lilly USA, LLC | $79.16 | 2024 | Verzenio |
| Seagen INC. | $76.50 | 2019-2023 | Padcev |
| Genzyme Corporation | $71.39 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $66.36 | 2019-2024 | Polivy, Phesgo |
| Sobi, INC | $58.03 | 2022-2023 | |
| Incyte Corporation | $55.87 | 2024 | Jakafi, Monjuvi |
| Deciphera Pharmaceuticals INC. | $46.30 | 2021-2024 | Qinlock |
| Glaxosmithkline, LLC. | $43.20 | 2024 | Zejula, Jemperli |
| Eisai INC. | $43.17 | 2021-2024 | |
| Coherus Oncology, INC. | $41.40 | 2023 | |
| Daiichi Sankyo INC. | $36.01 | 2022-2023 | Injectafer |
| Medtronic, INC. | $33.20 | 2023 | Osteocool Rf Ablation System |
| Foundation Medicine, INC. | $30.71 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $29.01 | 2023 | Tazverik |
| Stemline Therapeutics INC. | $24.28 | 2023 | Orserdu |
| Celltrion USA INC. | $20.03 | 2024 | Vegzelma |
| Array Biopharma INC | $18.78 | 2023 | Mektovi, Braftovi, Lorbrena |
| Aveo Pharmaceuticals, INC. | $18.74 | 2023 | Fotivda |
| Abbvie INC. | $18.40 | 2024 | |
| Taiho Oncology, INC. | $18.14 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $16.85 | 2023 | Epkinly |
| Kite Pharma, INC. | $16.27 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.76 | 2022 | |
| Amag Pharmaceuticals, INC. | $15.47 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.07 | 2020 | |
| Advanced Accelerator Applications | $13.02 | 2020 | |
| Beigene USA, INC. | $12.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kiraly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.